Glaxo & Pfizer rejig JV deal with Shionogi

ViiV Healthcare, a joint venture (JV) between drugs giants GlaxoSmithKline and Pfizer, is to acquire the exclusive global rights to the assets of Shionogi-ViiV Healthcare, a JV set up with Shionogi, the Japanese pharmaceuticals firm.

ViiV Healthcare, a joint venture (JV) between drugs giants GlaxoSmithKline and Pfizer, is to acquire the exclusive global rights to the assets of Shionogi-ViiV Healthcare, a JV set up with Shionogi, the Japanese pharmaceuticals firm.

The assets include the investigational medicine dolutegravir and other early stage HIV integrase inhibitor compounds.

As a result of the deal, Shionogi will receive an ongoing royalty and dividend stream, and will also receive a 10% equity in ViiV Healthcare. As a result of this, Glaxo's stake will be diluted to 76.5% and Pfizer's stake will be reduced to 13.5%.

Specifically, Shionogi will receive a royalty on net sales of the integrase inhibitor portfolio averaging in the high teens. For a defined period post-launch, while the franchise gets itself established, the royalty applies to sales above certain minimum thresholds; after that period, the royalty applies to all sales.

Shionogi will be entitled to representation on the ViiV Healthcare board, and will, for a defined period, continue to have ongoing involvement in the formulation of the development and commercialisation plans for the integrase inhibitor portfolio.

The deal kicks in on October 31st, and replaces the existing joint venture agreement between ViiV Healthcare and Shionogi.

With ViiV Healthcare in exclusive control of the development and commercialisation rights to the integrase inhibitor portfolio, the hope is that this will streamline research & development and commercial operations.

"Both ViiV Healthcare and Shionogi believe that now is the right time to simplify and evolve their existing arrangement," said David Redfern, Chairman of the board of Viiv Healthcare. "In doing so, we will deepen the relationship as shareholders and at board level. We will also unlock synergies through simplifying processes and avoiding duplication. We believe this new agreement will create long-term value for ViiV Healthcare and its shareholders," he added.

Glaxo will continue to consolidate 100% of ViiV Healthcare into its consolidated financial statements. The portion of ViiV Healthcare's after-tax profit attributable to the non-controlling interests of Pfizer and Shionogi will be reflected in the Glaxo income statement.

As a result of this transaction a non-cash accounting gain is expected to be recognised in Glaxo's fourth quarter 2012 non-core results.

Future royalty payments to Shionogi will be recorded as a reduction of the royalty obligation on Glaxo's balance sheet.

JH

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

NS&I brings back one-year fixed bonds with highest rates since 2010
Personal finance

NS&I brings back one-year fixed bonds with highest rates since 2010

NS&I’s one-year fixed bonds are back on sale after being pulled off the market in 2019 - but is the rate any good?
1 Feb 2023
How to invest like an ISA millionaire
Investments

How to invest like an ISA millionaire

We reveal the top funds and trusts ISA millionaires pumped their money into
6 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023